Libra Infusions Ltd
Libra Infusions Ltd develops and commercializes intravenous (IV) infusion therapies, primarily targeting hospital and specialty pharmacy channels.
Business. Libra Infusions Ltd (LBRA.DH) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Libra Infusions Ltd (LBRA.DH) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Libra Infusions Ltd has a fully diluted share count of 2,252,880 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry_config. As a result, a direct comparison to cohort medians for profitability or returns is not possible at this time.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown is provided, and there is no information on geographic distribution of sales.
Growth trajectory is also unclear, as the outlook section does not include numeric deltas or revenue history. The absence of forward-looking guidance or historical performance data limits the ability to assess near-term or long-term growth potential.
Risk factors include the inability to assess liquidity risk, which may affect the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilutive instruments or recent equity issuances. No adjustments were applied to the valuation metrics, and no specific risk drivers are identified in the risk assessment.
Recent events, including filings or transcripts, are not available in the provided data. The company's 10-K or 8-K filings, if any, are not accessible in the current dataset, limiting the ability to reference recent corporate developments.
- Libra Infusions Ltd operates in the pharmaceuticals industry, focusing on IV infusion therapies.
- The company has no dilution risk based on current share counts and no evidence of dilutive instruments.
- Liquidity risk could not be assessed due to missing balance-sheet data and lack of going-concern language.
- No profitability metrics or growth trajectory data are available for comparison to industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into business risk factors.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Libra Infusions Ltd Market data — financials · 2026-05-28
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on assets (FY 2025-12-31): 192.6%Derived (calculated)
- Return on equity (FY 2025-12-31): -240.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.25xDerived (calculated)
- Net margin (FY 2025-12-31): 136.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -2.33xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 19,646.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 100.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -51.2%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -89.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 206.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 104.7%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 165.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 126.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 133.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 207.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 71.1%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Pre-tax income (annual): USD 68.83MSEC XBRL filing
- Cost of revenue (annual): USD 24.35MSEC XBRL filing
- Total liabilities (annual): USD 63.55MSEC XBRL filing
- Capex (annual): USD 240.52KSEC XBRL filing
- Cash & equivalents (annual): USD 263.69KSEC XBRL filing
- Revenue (annual): USD 48.27MSEC XBRL filing